AW
ASBP

Avion Wealth’s Aspire Biopharma ASBP Stock Holding History

Avion Wealth’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Hold
45
– – ﹤0.01% 1821
2026
Q1 		$1K Hold
45
– – ﹤0.01% 1188
2025
Q4 		$7K Hold
45
– – ﹤0.01% 602
2025
Q3 		$11K Buy
+45
New +$22.5K ﹤0.01% 465

Other funds holding ASBP

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CA
Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.73B AUM 42.12% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $567M AUM 0.34% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Avion Wealth's ASBP Position: Q2 2026 in Review

Avion Wealth held its Aspire Biopharma (ASBP) position steady in Q2 2026 at 45 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1821.

Avion Wealth first reported a position in ASBP in Q3 2025 and has held it in 4 quarters since. The position peaked at $11K in Q3 2025. 13 funds tracked by Wall St. Rank hold ASBP as of Q2 2026.

  • Avion Wealth held 45 shares of Aspire Biopharma worth $0 as of Q2 2026.
  • Avion Wealth left its Aspire Biopharma share count unchanged in Q2 2026.
  • Aspire Biopharma made up ﹤0.01% of Avion Wealth's portfolio in Q2 2026, its #1821 holding.
  • Avion Wealth first reported a position in Aspire Biopharma in Q3 2025 and has held it in 4 quarters since.
  • Avion Wealth's Aspire Biopharma position peaked at $11K in Q3 2025.
  • 13 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2026.

Based on Avion Wealth's 13F filing for Q2 2026, filed 31 Jul 2026.